Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ESRRB | O95718 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.34 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.33 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15382926 | 0.88 | CA1 (0.37) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL22857667 | 0.83 | SMN1; SMN2 (0.34) | CHRNB2CHRNA4SMN1; SMN2CA1CA2 | |
| SCHEMBL7105090 | 0.81 | SMN1; SMN2 (0.46) | SMN1; SMN2ESRRBCA1CA2CA14 | |
| SCHEMBL10469243 | 0.79 | SLC22A1 (0.38) | CHRM2CHRM4CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL801049 | 0.78 | ABCB1 (0.43) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL5218474 | 0.77 | — | — | |
| SCHEMBL29531261 | 0.77 | SMN1; SMN2 (0.39) | CHRNB2CHRNA4SMN1; SMN2ESRRBCA1 | |
| SCHEMBL29531381 | 0.77 | SMN1; SMN2 (0.39) | CHRNB2CHRNA4SMN1; SMN2ESRRBCA1 | |
| SCHEMBL7136164 | 0.77 | SMN1; SMN2 (0.39) | CHRNB2CHRNA4SMN1; SMN2ESRRBCA1 | |
| SCHEMBL28472989 | 0.77 | CHRNB2 (0.39) | CHRNB2CHRNA4SMN1; SMN2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130822-A1 | LOW TOXICITY NMP SUBSTITUTES AND USES THEREOF | ADVANCION CORPORATION | 2023-04-27 | — | — | US | disclosed |
| US-20230130822-A1 | LOW TOXICITY NMP SUBSTITUTES AND USES THEREOF | ADVANCION CORPORATION | 2023-04-27 | — | — | US | disclosed |
| WO-2021163348-A2 | LOW TOXICITY NMP SUBSTITUTES AND USES THEREOF | ANGUS CHEMICAL COMPANY (US) | 2021-08-19 | — | — | WO | disclosed |
| EP-2013202-B1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130822-A1 | LOW TOXICITY NMP SUBSTITUTES AND USES THEREOF | NME4, NMBR, NMUR1 | CHRNB2 253/4885CHRNA4 576/4885CHRM2 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.